M. Azoulay et al. / Bioorg. Med. Chem. Lett. 16 (2006) 3147–3149
3149
References and notes
1. Staudinger, H.; Meyer, J. Helv. Chem. Acta 1919, 2,
635.
2. Gololobov, Y. G.; Kasukhin, L. F. Tetrahedron 1992, 48,
1353.
3. Saxon, E.; Bertozzi, C. R. Science 2000, 287, 2007.
4. Kiick, K. L.; Saxon, E.; Tirrell, D. A.; Bertozzi, C. R.
Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 19.
5. Nilsson, B. L.; Hondal, R. J.; Soellner, M. B.; Raines, R.
T. J. Am. Chem. Soc. 2003, 125, 5268.
6. Nilsson, B. L.; Kiessling, L. L.; Raines, R. T. Org. Lett.
2001, 3, 9.
7. Grandjean, C.; Boutonnier, A.; Guerreiro, C.; Fournier,
J.-M.; Mulard, L. A. J. Org. Chem. 2005, 70, 7123.
8. Hang, H. C.; Yu, C.; Pratt, M. R.; Bertozzi, C. R. J. Am.
Chem. Soc. 2004, 126, 6.
9. Vocadlo, D. J.; Bertozzi, C. R. Angew. Chem., Int. Ed.
2004, 43, 5338.
10. Saxon, E.; Luchansky, S. J.; Hang, H. C.; Yu, C.; Lee,
S. C.; Bertozzi, C. R. J. Am. Chem. Soc. 2002, 124,
14893.
Figure 2. (A) Incubation of compounds 1b (2.8 mM) and 2 (5.2 mM).
(B) Doxorubicin release was monitored by HPLC analysis, as a
function of time.
11. van Swieten, P. L.; Leeuwenburgh, M. A.; Kessler, B. M.;
Overkleeft, H. S. Org. Biomol. Chem. 2005, 3, 20.
12. Lemieux, G. A.; Granffenried, C. L.; Bertozzi, C. R.
J. Am. Chem. Soc. 2003, 125, 4708.
13. Prescher, J. A.; Dube, D. H.; Bertozzi, C. R. Nature 2004,
430, 873.
Supplementary data. After 3 h at 37 °C in aqueous
THF, the reaction appeared to approach 90%
completion.
In summary, we have successfully demonstrated for the
first time, the utility of the Staudinger ligation to liberate
a drug selectively and in good yield. In this report, we
have used an experimental model. We now wish to
extend our results to the complex environment of a liv-
ing cell. The Staudinger ligation seems perfectly suitable
for such an application, since the two reaction partners
are biocompatible and orthogonal to most biological
functionalities. Further studies to take advantage of this
new drug-release method are currently in progress.
14. Wakselman, M. Nouv. J. Chim. 1983, 7, 439.
15. Carl, P. L.; Chakravarty, P. K.; Katzenellenbogen, J. A.
J. Med. Chem. 1981, 24, 479.
16. Duimstra, J. A.; Femia, F. J.; Meade, T. J. J. Am. Chem.
Soc. 2005, 127, 12847.
17. Lee, M. R.; Baek, K. H.; Jin, H. J.; Jung, Y. G.; Shin, I.
Angew. Chem., Int. Ed. 2004, 43, 1675.
18. Azoulay, M.; Florent, J.-C.; Monneret, C.; Gesson, J.-P.;
Jacquesy, J.-C.; Tillequin, F.; Koch, M.; Bosslet, K.;
Czech, J.; Hoffman, D. Anti-Cancer Drug Des. 1995, 10,
441.
19. Harapanhalli, R. S.; McLaughlin, L. W.; Howell, R. W.;
Rao, D. V.; Adelstein, S. J.; Kassis, A. I. J. Med. Chem.
1996, 39, 4804.
Acknowledgment
20. Herd, O.; Heßler, A.; Hingst, M.; Tepper, M.; Stelzer, O.
J. Organomet. Chem. 1996, 522, 69.
We thank S. Thirot for running the HPLC experiments.
21. Lin, G.; Lai, C. Y.; Liao, W. C. Bioorg. Med. Chem. 1999,
7, 2683.
22. Sinhababu, A. K.; Borchardt, R. T. Tetrahedron Lett.
1983, 24, 227.
Supplementary data
Supplementary data associated with this article can be
23. Marsh, I. R.; Bradley, M. Tetrahedron 1997, 53, 17317.
24. Young, L. J.; Richards, W. L.; Bouzelet, W.; Tsai, L. L.;
Boutwell, R. K. Cancer Res. 1978, 38, 3697.